GenSight Biologics Delays 2025 Half-Year Financial Results Announcement

GenSight Biologics, a Paris-based biopharma company, announced the postponement of its 2025 half-year financial results. Originally slated for September 19, the release is now scheduled for September 29, 2025. This delay ensures the completion of audit procedures to the highest standards by the Company's external auditors.

The postponement is solely due to the time required for the audit, not because of any issues with the financial statements. It allows GenSight Biologics to fully comply with regulatory requirements, maintaining accurate and transparent financial reporting.

The company's Audit Committee and Board of Directors meetings are rescheduled to September 24 and September 26, respectively. The financial results will be accessible on the company's website immediately after the announcement.